OLD Second National Bank of Aurora Raises Stake in Zoetis Inc. $ZTS

Key Points

• OLD Second National Bank of Aurora increased its stake in Zoetis Inc. by 17.1%, acquiring an additional 2,000 shares, bringing its total holdings to 13,693 shares valued at approximately $2,135,000.
• Multiple large investors, including Vanguard Group Inc. and Polen Capital Management LLC, have increased their positions in Zoetis during the same quarter, indicating strong institutional interest in the company.
• Zoetis reported a quarterly earnings per share of $1.76, beating expectations, and set its FY 2025 guidance at 6.300-6.400 EPS, with analysts forecasting a consensus rating of Moderate Buy and a target price of $200.88.

OLD Second National Bank of Aurora lifted its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 17.1% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 13,693 shares of the company's stock after purchasing an additional 2,000 shares during the period. OLD Second National Bank of Aurora's holdings in Zoetis were worth $2,135,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in Zoetis by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 41,556,164 shares of the company's stock worth $6,842,222,000 after buying an additional 189,287 shares during the period. Polen Capital Management LLC lifted its position in shares of Zoetis by 17.6% in the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company's stock valued at $1,448,401,000 after acquiring an additional 1,313,653 shares in the last quarter. Northern Trust Corp raised its stake in Zoetis by 1.2% during the 1st quarter. Northern Trust Corp now owns 6,504,902 shares of the company's stock valued at $1,071,032,000 after purchasing an additional 78,508 shares during the period. Goldman Sachs Group Inc. raised its stake in Zoetis by 2.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company's stock valued at $847,293,000 after purchasing an additional 109,791 shares during the period. Finally, Brown Advisory Inc. raised its stake in Zoetis by 7.6% during the 1st quarter. Brown Advisory Inc. now owns 4,408,542 shares of the company's stock valued at $725,866,000 after purchasing an additional 312,746 shares during the period. Hedge funds and other institutional investors own 92.80% of the company's stock.

Zoetis Price Performance

NYSE:ZTS opened at $146.46 on Friday. The business has a 50 day simple moving average of $149.89 and a 200-day simple moving average of $155.26. Zoetis Inc. has a 1 year low of $139.34 and a 1 year high of $196.55. The firm has a market capitalization of $64.91 billion, a price-to-earnings ratio of 25.21, a PEG ratio of 2.36 and a beta of 0.90. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. During the same quarter in the prior year, the firm posted $1.56 EPS. Zoetis's quarterly revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Analysts Set New Price Targets

ZTS has been the subject of a number of research analyst reports. Stifel Nicolaus lowered shares of Zoetis from a "buy" rating to a "hold" rating and cut their price objective for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Argus reaffirmed a "buy" rating and issued a $190.00 target price on shares of Zoetis in a report on Tuesday, September 9th. Leerink Partners cut Zoetis from an "outperform" rating to a "market perform" rating and reduced their target price for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Piper Sandler raised their price target on Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Finally, Leerink Partnrs downgraded Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Five investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, Zoetis presently has a consensus rating of "Moderate Buy" and a consensus target price of $200.88.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.